Current Clinical Trials
All Clinical Trials
Biliary Tract
NAME: PanTumor3- Biliary Tree
What type of cancer is this for: Liver, gallbladder, bile ducts
Phase: II
Who is this trial for: Men and women who have cancer in their biliary tract: liver and/or gallbladder and/or bile ducts that has spread to other parts of the body and cannot be taken out.
What biomarkers are involved? Your cancer cells must be positive for Trop2
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see how well the study drug (Dato-DXd) works on biliary tract cancers that have spread, as well as how safe the drug is.
Need to know: You need to have tried either Gemzar & Carboplatin OR Gemzar & Cisplatin in the past.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Breast
Name of this trial: TROPION-Breast-05
What type of cancer is this for? Metastatic Triple Negative Breast Cancer (TNBC)
Who is this trial for? Patients who have recurrent, locally inoperable, metastatic breast cancer. Must be ER-, PR-, HER2-.
What biomarkers are involved? PD-L1 positive
What is the National Clinical Trial #? NCT06103864
Brief summary of this trial: Open-label 2 potential arms to be randomized to, randomized on a 1:1 ratio. Arm 1: Investigational drug Dato-DXd + Durvalumab, Arm 2: Pembrolizumab with chemotherapy of providers choice.
Need to know: Must not have had any prior treatment for your cancer in metastatic setting. Must be negative for hormone receptors and HER2 negative. PD-L1 will be confirmed by sponsor. Eye exams for screening is a requirement for this trial and will continue if randomized to the investigational arm with Dato-DXd.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of Trial: Tropion 04
What type of cancer is this for? Triple Negative Breast Cancer
Phase of this trial? 3
Who is the trial for? Men or women diagnosed with Stage II or III bilateral or unilateral primary invasive breast cancer. who have not yet had surgery or plan to not have surgery.
What biomarkers/mutations are necessary? HER2-, HR – or HR low
What is the National Clinical Trials info? NCT06112379
Brief summary of Trial: The is a randomized study looking at effectiveness and safety of pre-surgical Dato-DXd plus durvalumab, followed by post-surgical durvalumab with or without chemotherapy. Compared with pre-surgical pembrolizumab plus chemo, followed by post-surgical pembrolizumab with or without chemotherapy, in previously untreated participants.
Need to know: Stage II or III localized breast cancer patients who require pre-surgical treatment, and is newly diagnosed with breast cancer that is triple negative, or low hormone receptor negative.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of Trial? Capitello-292
Phase of this trial? Phase 3
Who is this trial for? Men and Women with hormone positive, HER2 negative breast cancer that is locally advanced and inoperable.
What biomarkers are involved? None
Clinical Trial # NCT04862663
Brief Summary of Trial: This is a randomized 1:1 trial that is looking at new drug Capivasertib in combination with anti-hormone drug and a CDK4/6 inhibitor (oral drug), vs. anti-hormone drug plus CDK4/6 inhibitor. The study is looking for which works best.
Need to Know: Must have relapsed on or within 12 months of completing first line endocrine therapy (such as Tamoxifen, or another AI), maximum of 1 line of chemotherapy in advanced disease setting.
Where is this trial available? Cancer and Hematology Centers and other sites nationwide, please click on link for other locations,
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: ELAINE 3
What type of cancer is this for? BREAST
Phase of this trial: Phase III
Who is this trial for? Men and Women with Breast Cancer that has spread to other parts of the body.
What biomarkers are involved? You must have estrogen receptor positive, HER2 negative Breast Cancer with an ESR1 Mutation
What is National Clinical Trial #? NCT05696626
Brief summary of trial: This trial compares how effective and safe the combination of Lasofoxifene and Abemaciclib is, compared to the combination of Fulvestrant and Abemaciclib. Lasofoxifene and Abemaciclib are both pills, and Fulvestrant is an injection.
Need to know: You must have tried Ribociclib or palbociclib-based treatment before.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: GILEAD ASCENT-05
What type of cancer is this for? BREAST Cancer Triple Negative
Phase of this trial: Phase III
Who is this trial for? Men and Women with Breast Cancer early stage not cured with chemotherapy and surgery.
What biomarkers are involved? You must have estrogen receptor negative, progesterone receptor negative, and HER2 negative Breast Cancer
What is National Clinical Trial #? NCT05633654
Brief summary of trial: This trial compares how effective and safe the combination of Sacituzumab Govitecan and Pembrolizumab is, compared to treatment of physician’s choice in patients with triple negative breast cancer who have residual invasive disease after surgery and neoadjuvant therapy.
Need to know: Must have had neoadjuvant treatment and surgery for breast surgery with residual disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Colorectal
Name of this trial: CODEBREAK 301
What type of cancer is this for? COLON
Phase of this trial? Phase III
Who is this trial for? Men and women with colon cancer that has spread to other parts of the body.
What biomarkers are involved? Your cancer must have a KRAS P.G12C mutation.
What is the National Clinical Trial# NCT04303780
Brief summary of trial: This trial is randomized 1:1 to either Sotorarsib+Panitumumab+FOLFIRI (standard chemo regimen) vs. standard of care chemotherapy regimens FOLFOX or FOLFIRI +/- Avastin. The study is investigating which of these treatment plans shows longer overall survival and progression-free survival in metastatic colon cancer patients.
Need to know: You may have had treatment for your colon cancer before it spread, but now that it has spread, this has to be the first treatment you receive for it.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: CARDIFF-004
What type of cancer is this for? COLORECTAL cancer
Phase of this trial? Phase II
Who is this trial for? Men and Women with colorectal cancer that has spread but they have never had treatment for their disease.
What biomarkers are involved? Your cancer must have a KRAS or NRAS mutation.
What is the National Clinical Trial# NCT06106308
Brief summary of trial: This trial looks at how well two different doses of the study drug (onvansertib) work when combined with two different chemotherapy plans.
Need to know: You may have had treatment for your colorectal cancer before it spread, but now that it has spread, this has to be the first treatment you receive for it.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Esophageal
NAME: GEMINI GASTRIC
What type of cancer is this for? Stomach and where the stomach and esophagus join together
Phase: II
Who is this trial for: Men and women who have stomach cancer, or cancer where the stomach and esophagus meet, that cannot be removed or has spread to other parts of the body
What biomarkers are involved? Your tumor CANNOT be positive for HER-2.
What is National Clinical Trial #? NCT05702229
Brief summary of trial: This trial is looking to see how well two new drugs (MEDI5752 and AZD2936) work with chemotherapy plans that already exist.
Need to know: This must be the first treatment you receive since finding out your cancer has spread.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: KEYMAKER-U06, MK-3475-06C
What type of cancer is this for? Locally advanced unresectable/metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
Who is this trial for? Newly diagnosed advanced gastroesophageal, gastric, esophageal cancers, that are not treatable with radiation or surgery.
What biomarkers are involved? Must be HER2 negative
What is the National Clinical Trial #? NCT06469944
Brief summary of this trial: This is a randomized trial with 2 different arms. Arm 1 is treatment with standard of care drugs, Pembrolizumab + chemotherapy. Arm 2 is the investigational arm where patient would receive investigational drug (MK-2870) + Pembrolizumab + chemotherapy. 1:1 randomization.
Need to know: Locally advanced tumor that cannot be treated with surgery or radiation and cannot have been previously treated.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 email clinicaltrials@chcwm.com
Name of this trial: KEYMAKER-U06, MK-3475-06D
What type of cancer is this for? Gastroesophageal junction, Gastroesophageal adenocarcinoma, Esophageal Adenocarcinoma
Who is this trial for? Patients who have had First Line treatment for Gastric adenocarcinoma, GEJ adenocarcinoma, or esophageal carcinoma, and had disease progression during or after treatment.
What biomarkers are involved? Must be HER2 negative
What is the National Clinical Trial #? NCT06445972
Brief summary of this trial: This is a randomized trial with 2 arms. Arm 1 is standard of care Ramucirumab + paclitaxel, and Arm 2 is Investigational Drug (MK-2870) + Paclitaxel. This is a 1:1 randomization.
Need to know: Patient must have progressed during or after first line treatment for this type of cancer. First line therapy containing any Platinum drug with 5-FU, with or without immunotherapy.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 email clinicaltrials@chcwm.com
Gallbladder
NAME: PanTumor3- Biliary Tree
What type of cancer is this for: Liver, gallbladder, bile ducts
Phase: II
Who is this trial for: Men and women who have cancer in their biliary tract: liver and/or gallbladder and/or bile ducts that has spread to other parts of the body and cannot be taken out.
What biomarkers are involved? Your cancer cells must be positive for Trop2
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see how well the study drug (Dato-DXd) works on biliary tract cancers that have spread, as well as how safe the drug is.
Need to know: You need to have tried either Gemzar & Carboplatin OR Gemzar & Cisplatin in the past.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Gastric
NAME: GEMINI GASTRIC
What type of cancer is this for? Stomach and where the stomach and esophagus join together
Phase: II
Who is this trial for: Men and women who have stomach cancer, or cancer where the stomach and esophagus meet, that cannot be removed or has spread to other parts of the body
What biomarkers are involved? Your tumor CANNOT be positive for HER-2.
What is National Clinical Trial #? NCT05702229
Brief summary of trial: This trial is looking to see how well two new drugs (MEDI5752 and AZD2936) work with chemotherapy plans that already exist.
Need to know: This must be the first treatment you receive since finding out your cancer has spread.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: KEYMAKER-U06, MK-3475-06C
What type of cancer is this for? Locally advanced unresectable/metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
Who is this trial for? Newly diagnosed advanced gastroesophageal, gastric, esophageal cancers, that are not treatable with radiation or surgery.
What biomarkers are involved? Must be HER2 negative
What is the National Clinical Trial #? NCT06469944
Brief summary of this trial: This is a randomized trial with 2 different arms. Arm 1 is treatment with standard of care drugs, Pembrolizumab + chemotherapy. Arm 2 is the investigational arm where patient would receive investigational drug (MK-2870) + Pembrolizumab + chemotherapy. 1:1 randomization.
Need to know: Locally advanced tumor that cannot be treated with surgery or radiation and cannot have been previously treated.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 email clinicaltrials@chcwm.com
Name of this trial: KEYMAKER-U06, MK-3475-06D
What type of cancer is this for? Gastroesophageal junction, Gastroesophageal adenocarcinoma, Esophageal Adenocarcinoma
Who is this trial for? Patients who have had First Line treatment for Gastric adenocarcinoma, GEJ adenocarcinoma, or esophageal carcinoma, and had disease progression during or after treatment.
What biomarkers are involved? Must be HER2 negative
What is the National Clinical Trial #? NCT06445972
Brief summary of this trial: This is a randomized trial with 2 arms. Arm 1 is standard of care Ramucirumab + paclitaxel, and Arm 2 is Investigational Drug (MK-2870) + Paclitaxel. This is a 1:1 randomization.
Need to know: Patient must have progressed during or after first line treatment for this type of cancer. First line therapy containing any Platinum drug with 5-FU, with or without immunotherapy.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 email clinicaltrials@chcwm.com
Biliary Tract Cancer Clinical Trials
Biliary Tract
NAME: PanTumor3- Biliary Tree
What type of cancer is this for: Liver, gallbladder, bile ducts
Phase: II
Who is this trial for: Men and women who have cancer in their biliary tract: liver and/or gallbladder and/or bile ducts that has spread to other parts of the body and cannot be taken out.
What biomarkers are involved? Your cancer cells must be positive for Trop2
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see how well the study drug (Dato-DXd) works on biliary tract cancers that have spread, as well as how safe the drug is.
Need to know: You need to have tried either Gemzar & Carboplatin OR Gemzar & Cisplatin in the past.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Bladder Cancer Clinical Trials
Breast Cancer Clinical Trials
Breast
Name of this trial: TROPION-Breast-05
What type of cancer is this for? Metastatic Triple Negative Breast Cancer (TNBC)
Who is this trial for? Patients who have recurrent, locally inoperable, metastatic breast cancer. Must be ER-, PR-, HER2-.
What biomarkers are involved? PD-L1 positive
What is the National Clinical Trial #? NCT06103864
Brief summary of this trial: Open-label 2 potential arms to be randomized to, randomized on a 1:1 ratio. Arm 1: Investigational drug Dato-DXd + Durvalumab, Arm 2: Pembrolizumab with chemotherapy of providers choice.
Need to know: Must not have had any prior treatment for your cancer in metastatic setting. Must be negative for hormone receptors and HER2 negative. PD-L1 will be confirmed by sponsor. Eye exams for screening is a requirement for this trial and will continue if randomized to the investigational arm with Dato-DXd.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of Trial: Tropion 04
What type of cancer is this for? Triple Negative Breast Cancer
Phase of this trial? 3
Who is the trial for? Men or women diagnosed with Stage II or III bilateral or unilateral primary invasive breast cancer. who have not yet had surgery or plan to not have surgery.
What biomarkers/mutations are necessary? HER2-, HR – or HR low
What is the National Clinical Trials info? NCT06112379
Brief summary of Trial: The is a randomized study looking at effectiveness and safety of pre-surgical Dato-DXd plus durvalumab, followed by post-surgical durvalumab with or without chemotherapy. Compared with pre-surgical pembrolizumab plus chemo, followed by post-surgical pembrolizumab with or without chemotherapy, in previously untreated participants.
Need to know: Stage II or III localized breast cancer patients who require pre-surgical treatment, and is newly diagnosed with breast cancer that is triple negative, or low hormone receptor negative.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of Trial? Capitello-292
Phase of this trial? Phase 3
Who is this trial for? Men and Women with hormone positive, HER2 negative breast cancer that is locally advanced and inoperable.
What biomarkers are involved? None
Clinical Trial # NCT04862663
Brief Summary of Trial: This is a randomized 1:1 trial that is looking at new drug Capivasertib in combination with anti-hormone drug and a CDK4/6 inhibitor (oral drug), vs. anti-hormone drug plus CDK4/6 inhibitor. The study is looking for which works best.
Need to Know: Must have relapsed on or within 12 months of completing first line endocrine therapy (such as Tamoxifen, or another AI), maximum of 1 line of chemotherapy in advanced disease setting.
Where is this trial available? Cancer and Hematology Centers and other sites nationwide, please click on link for other locations,
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: ELAINE 3
What type of cancer is this for? BREAST
Phase of this trial: Phase III
Who is this trial for? Men and Women with Breast Cancer that has spread to other parts of the body.
What biomarkers are involved? You must have estrogen receptor positive, HER2 negative Breast Cancer with an ESR1 Mutation
What is National Clinical Trial #? NCT05696626
Brief summary of trial: This trial compares how effective and safe the combination of Lasofoxifene and Abemaciclib is, compared to the combination of Fulvestrant and Abemaciclib. Lasofoxifene and Abemaciclib are both pills, and Fulvestrant is an injection.
Need to know: You must have tried Ribociclib or palbociclib-based treatment before.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: GILEAD ASCENT-05
What type of cancer is this for? BREAST Cancer Triple Negative
Phase of this trial: Phase III
Who is this trial for? Men and Women with Breast Cancer early stage not cured with chemotherapy and surgery.
What biomarkers are involved? You must have estrogen receptor negative, progesterone receptor negative, and HER2 negative Breast Cancer
What is National Clinical Trial #? NCT05633654
Brief summary of trial: This trial compares how effective and safe the combination of Sacituzumab Govitecan and Pembrolizumab is, compared to treatment of physician’s choice in patients with triple negative breast cancer who have residual invasive disease after surgery and neoadjuvant therapy.
Need to know: Must have had neoadjuvant treatment and surgery for breast surgery with residual disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Colorectal Cancer Clinical Trials
Colorectal
Name of this trial: CODEBREAK 301
What type of cancer is this for? COLON
Phase of this trial? Phase III
Who is this trial for? Men and women with colon cancer that has spread to other parts of the body.
What biomarkers are involved? Your cancer must have a KRAS P.G12C mutation.
What is the National Clinical Trial# NCT04303780
Brief summary of trial: This trial is randomized 1:1 to either Sotorarsib+Panitumumab+FOLFIRI (standard chemo regimen) vs. standard of care chemotherapy regimens FOLFOX or FOLFIRI +/- Avastin. The study is investigating which of these treatment plans shows longer overall survival and progression-free survival in metastatic colon cancer patients.
Need to know: You may have had treatment for your colon cancer before it spread, but now that it has spread, this has to be the first treatment you receive for it.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: CARDIFF-004
What type of cancer is this for? COLORECTAL cancer
Phase of this trial? Phase II
Who is this trial for? Men and Women with colorectal cancer that has spread but they have never had treatment for their disease.
What biomarkers are involved? Your cancer must have a KRAS or NRAS mutation.
What is the National Clinical Trial# NCT06106308
Brief summary of trial: This trial looks at how well two different doses of the study drug (onvansertib) work when combined with two different chemotherapy plans.
Need to know: You may have had treatment for your colorectal cancer before it spread, but now that it has spread, this has to be the first treatment you receive for it.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Esophageal Cancer Clinical Trials
Esophageal
NAME: GEMINI GASTRIC
What type of cancer is this for? Stomach and where the stomach and esophagus join together
Phase: II
Who is this trial for: Men and women who have stomach cancer, or cancer where the stomach and esophagus meet, that cannot be removed or has spread to other parts of the body
What biomarkers are involved? Your tumor CANNOT be positive for HER-2.
What is National Clinical Trial #? NCT05702229
Brief summary of trial: This trial is looking to see how well two new drugs (MEDI5752 and AZD2936) work with chemotherapy plans that already exist.
Need to know: This must be the first treatment you receive since finding out your cancer has spread.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: KEYMAKER-U06, MK-3475-06C
What type of cancer is this for? Locally advanced unresectable/metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
Who is this trial for? Newly diagnosed advanced gastroesophageal, gastric, esophageal cancers, that are not treatable with radiation or surgery.
What biomarkers are involved? Must be HER2 negative
What is the National Clinical Trial #? NCT06469944
Brief summary of this trial: This is a randomized trial with 2 different arms. Arm 1 is treatment with standard of care drugs, Pembrolizumab + chemotherapy. Arm 2 is the investigational arm where patient would receive investigational drug (MK-2870) + Pembrolizumab + chemotherapy. 1:1 randomization.
Need to know: Locally advanced tumor that cannot be treated with surgery or radiation and cannot have been previously treated.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 email clinicaltrials@chcwm.com
Name of this trial: KEYMAKER-U06, MK-3475-06D
What type of cancer is this for? Gastroesophageal junction, Gastroesophageal adenocarcinoma, Esophageal Adenocarcinoma
Who is this trial for? Patients who have had First Line treatment for Gastric adenocarcinoma, GEJ adenocarcinoma, or esophageal carcinoma, and had disease progression during or after treatment.
What biomarkers are involved? Must be HER2 negative
What is the National Clinical Trial #? NCT06445972
Brief summary of this trial: This is a randomized trial with 2 arms. Arm 1 is standard of care Ramucirumab + paclitaxel, and Arm 2 is Investigational Drug (MK-2870) + Paclitaxel. This is a 1:1 randomization.
Need to know: Patient must have progressed during or after first line treatment for this type of cancer. First line therapy containing any Platinum drug with 5-FU, with or without immunotherapy.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 email clinicaltrials@chcwm.com
Gallbladder Cancer Clinical Trials
Gallbladder
NAME: PanTumor3- Biliary Tree
What type of cancer is this for: Liver, gallbladder, bile ducts
Phase: II
Who is this trial for: Men and women who have cancer in their biliary tract: liver and/or gallbladder and/or bile ducts that has spread to other parts of the body and cannot be taken out.
What biomarkers are involved? Your cancer cells must be positive for Trop2
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see how well the study drug (Dato-DXd) works on biliary tract cancers that have spread, as well as how safe the drug is.
Need to know: You need to have tried either Gemzar & Carboplatin OR Gemzar & Cisplatin in the past.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Gastric Cancer Clinical Trials
Gastric
NAME: GEMINI GASTRIC
What type of cancer is this for? Stomach and where the stomach and esophagus join together
Phase: II
Who is this trial for: Men and women who have stomach cancer, or cancer where the stomach and esophagus meet, that cannot be removed or has spread to other parts of the body
What biomarkers are involved? Your tumor CANNOT be positive for HER-2.
What is National Clinical Trial #? NCT05702229
Brief summary of trial: This trial is looking to see how well two new drugs (MEDI5752 and AZD2936) work with chemotherapy plans that already exist.
Need to know: This must be the first treatment you receive since finding out your cancer has spread.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: KEYMAKER-U06, MK-3475-06C
What type of cancer is this for? Locally advanced unresectable/metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
Who is this trial for? Newly diagnosed advanced gastroesophageal, gastric, esophageal cancers, that are not treatable with radiation or surgery.
What biomarkers are involved? Must be HER2 negative
What is the National Clinical Trial #? NCT06469944
Brief summary of this trial: This is a randomized trial with 2 different arms. Arm 1 is treatment with standard of care drugs, Pembrolizumab + chemotherapy. Arm 2 is the investigational arm where patient would receive investigational drug (MK-2870) + Pembrolizumab + chemotherapy. 1:1 randomization.
Need to know: Locally advanced tumor that cannot be treated with surgery or radiation and cannot have been previously treated.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 email clinicaltrials@chcwm.com
Name of this trial: KEYMAKER-U06, MK-3475-06D
What type of cancer is this for? Gastroesophageal junction, Gastroesophageal adenocarcinoma, Esophageal Adenocarcinoma
Who is this trial for? Patients who have had First Line treatment for Gastric adenocarcinoma, GEJ adenocarcinoma, or esophageal carcinoma, and had disease progression during or after treatment.
What biomarkers are involved? Must be HER2 negative
What is the National Clinical Trial #? NCT06445972
Brief summary of this trial: This is a randomized trial with 2 arms. Arm 1 is standard of care Ramucirumab + paclitaxel, and Arm 2 is Investigational Drug (MK-2870) + Paclitaxel. This is a 1:1 randomization.
Need to know: Patient must have progressed during or after first line treatment for this type of cancer. First line therapy containing any Platinum drug with 5-FU, with or without immunotherapy.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 email clinicaltrials@chcwm.com
Kidney Cancer Clinical Trials
Kidney
Leukemia Clinical Trials
Leukemia
Liver Cancer Clinical Trials
Liver
NAME: PanTumor3- Biliary Tree
What type of cancer is this for: Liver, gallbladder, bile ducts
Phase: II
Who is this trial for: Men and women who have cancer in their biliary tract: liver and/or gallbladder and/or bile ducts that has spread to other parts of the body and cannot be taken out.
What biomarkers are involved? Your cancer cells must be positive for Trop2
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see how well the study drug (Dato-DXd) works on biliary tract cancers that have spread, as well as how safe the drug is.
Need to know: You need to have tried either Gemzar & Carboplatin OR Gemzar & Cisplatin in the past.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Lung Cancer Clinical Trials
Lung
Name of this trial: AMG 193
What type of cancer is this for? Non-small Cell Lung Cancer
Who is this trial for? Patients who have been previously treated for locally advanced, unresectable, or metastatic disease.
What biomarkers are involved? MTAP deletion
What is the National Clinical Trial #? NCT06593522
Brief summary of this trial: This is an open label trial looking at safety and efficacy of oral drug AMG 193. The first part of trial is exploring 2 different doses of study drug.
Need to know: Patients must have had at least prior line of chemotherapy for locally advanced/unresectable/metastatic disease. If disease recurrence has occurred within 6 months of curative therapy, you are eligible for enrollment. Frequent lab draws for the first cycle of study, then goes to monthly visits. Medication is taken 1 time a day and can be taken with or without food.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: Interpath-002
What type of cancer is this for? Resected Stage II, IIIA, IIIB, non-small cell Lung Cancer
Who is this trial for? Patients who have had their lung cancer completed resected, with no evidence of disease and have completed post-surgical chemotherapy.
What biomarkers are involved? none
What is the National Clinical Trial #? NCT06077760
Brief summary of this trial: This is a phase 3, double-blinded, randomized, placebo- and active comparator controlled trial of V940 vaccine or placebo, plus pembrolizumab after non-small lung cancer resection. This is considered adjuvant treatment (treatment given after primary treatment to reduce risk of cancer returning) where all participants will receive pembrolizumab immunotherapy with/without vaccine.
Need to know: Randomization is 1:1 for either vaccine or placebo, no one will know what patient is receiving (double-blinded).Vaccine is tailored to each individual based on their cellular makeup and is given as injection in the muscle every 3 weeks. Pembrolizumab is given IV every 6 weeks.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: KRAScendo
What type of cancer is this for? Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Stage IIIc-Stage IV
Who is this trial for? Patients who have progressed during or following treatment with at least 1 prior line of therapy, but no more than 3 prior lines of therapy in the metastatic setting.
What biomarkers are involved? KRAS G12C
What is the National Clinical Trial #? NCT06497556
Brief summary of this trial: This is a phase 3, randomized trial evaluating safety and efficacy of new oral drug Divarasib. Patient will be randomized to either study drug Divarasib, Sotorasib (standard of care drug), or Adagrasib (standard of care drug). All medications are oral and provided by sponsor or via medication card.
Need to know: Genetic mutations will be confirmed from central lab using previous biopsy tissue. Scans will occur every 6 weeks to confirm treatment efficacy. Each cycle of treatment is 21 days, and the first couple cycles will require more frequent visits and labs to confirm tolerability and safety, further cycle visits will spread out to monthly.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: DeLLphi-305
What type of cancer is this for? Extensive stage, small cell Lung cancer.
Who is this trial for? Newly diagnosed patients with extensive stage small cell lung cancer, who are either starting first line treatment, or completed induction treatment.
What biomarkers are involved? N/A
What is the National Clinical Trial #? NCT06211036
Brief summary of this trial: Phase 3 open-label trial looking at new drug Tarlatamab with Durvalumab, vs. Durvalumab alone post induction therapy for extensive-stage small cell lung cancer.
Need to know: This is first line treatment for extensive stage small cell lung cancer. If you previously had Limited Stage Small cell lung cancer and it has been over 6 months since treatment, you may be eligible. Must have completed 4 cycles of chemotherapy prior to enrollment.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: LIVIGNO-4
What type of cancer is this for? Non-Small Cell Lung Cancer, Non-Squamous Cell Cytology
Who is this trial for? Patients with Lung Cancer that has metastasized to other areas of body who have never received treatment for their disease.
What biomarkers are involved? NO EGFR, or NO ALK mutations allowed.
What is the National Clinical Trial #? NCT06236438
Brief summary of this trial: Randomized study looking at Livmoniplimab plus Budigalimab in combination with standard of care chemotherapy vs. Pembrolizumab plus standard of care chemotherapy.
Need to know: Patients must not have had any treatment for their metastatic lung cancer to be eligible for this trial. Patients may have received treatment for earlier stage of lung cancer as long as it was 6 months or greater from the time of progression of disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of Trial: JUSTAR-001
What type of cancer is this trial for? Limited Stage, Small-cell Lung cancer
Who is this trial for? Patients with limited stage small cell lung cancer who have not progressed after initial chemotherapy/radiation.
What biomarkers are involved? None
National Clinical Trial # NCT06095583
Brief Summary of trial: Study is looking to compare and evaluate efficacy of new drug Tifcemalimab combined with Toripalimab vs. PLACEBO after consolidation chemotherapy for small cell lung cancer. This is a blinded study, so patients will not know whether they are receiving investigational drug or not.
Need to know information: Must not have received prior immunotherapy for small-cell lung cancer, and cannot have extensive stage/metastatic small cell lung cancer.
Where is this trial available? The Cancer and Hematology Centers and other sites nationwide, please click on link above for other potential sites.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name: Pacific-9
What kind of cancer is this for? Non-small cell lung cancer
Phase: III
Who is this trial for? Men and women with locally advanced (Stage III) non-small cell lung cancer that cannot be removed by a doctor.
What biomarkers are involved? PD-L1, EGFR and ALK
What is National Clinical Trial #? NCT05221840
Brief summary of trial: This study is looking to prove that durvalumab and oleclumab work better than durvalumab and a placebo (harmless medication) do.
Need to know: You must have had a chemo plan that included either Cisplatin or Carboplatin, along with radiation at the same time you were getting chemotherapy. Your disease cannot have grown any bigger since chemo and radiation finished.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of Trial? Sunray-01
What type of Cancer is this for? Non-small cell Lung cancer
What biomarkers are involved? KRAS G12C-mutation, PD-L1 expression
National Clinical Trials # NCT06119581
Brief Summary of trial: Locally advanced, or metastatic non-small cell lung cancer, never treated. This is first line treatment with study drug LY3537982 (pill) or placebo, in combination with immunotherapy and chemotherapy.
Need to know information: No prior treatment for lung cancer. We will do mutation testing to determine eligibility from prior biopsy/blood sample. This is a blinded trial with study drug LY3537982/placebo. All patients will receive the oral drug but the provider nor research team will know whether you are getting drug/placebo.
Where is this trial available? The Cancer and Hematology Centers and other sites nationwide, please click on link above for other potential sites.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: Tropion-Lung 10
What type of cancer is this for? Locally advanced or Metastatic Non-Squamous Non-small cell lung cancer
Who is this trial for? Patients who have lung cancer that is not treatable with curative surgery of chemoradiation. Patients must not have received prior treatment for advanced stage non-small cell lung cancer.
What biomarkers are involved? PD-L1 expression of ≥ 50% which will be determined by central lab.
What is the National Clinical Trial #? NCT06357533
Brief summary of this trial: Phase 3, Randomized, global trial of Datopotamab Deruxtecan in combination with Rilvegostomig, or Rilvegostomig monotherapy, or Pembrolizumab monotherapy. Randomization is a 2:1:2 for the 3 different arms.
Need to know: Must be non-squamous histology. Will require baseline eye exam for all arms of trial. Patients randomized to Datopotamab Deruxtecan will need further eye exams throughout trial.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Lymphoma Clinical Trials
Lymphoma
Name of this trial: Keyform-008
What type of cancer is this for? Relapsed or Refractory Classical Hodgkins Lymphoma
Who is this trial for? Patients with Classical Hodkins Lymphoma who had progressed or recurred and exhausted all available treatment options, including autologous stem-cell transplant and/or other salvage chemotherapy.
What biomarkers are involved? PD-L1 positive
What is the National Clinical Trial #? NCT05508867
Brief summary of this trial: Phase 3, randomized Clinical study of MK-4280A (Coformulated Favezelimab/Pembrolizumab (MK-3475)) Versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma
Need to know: This trial is for patients with classical Hodgkin’s lymphoma who previously had treatment with transplant or chemotherapy, or for those who are not eligible for transplant. Ineligibility for transplant includes inability for successful collection of stem cells, elderly, or has refused transplant. Patient must also have had a previous anti-PD-L1 medication within last 12 weeks and have progressed while on treatment.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: Olympia-2, R1979-ONC-2075
What type of cancer is this trial for? Untreated Follicular Lymphoma
Trial Phase: 3
Who is this trial for? This trial is for newly diagnosed or untreated patients with Follicular Lymphoma.
What biomarkers are required for eligibility? CD20+ Follicular Lymphoma
National Clinical Trial #? NCT06097364
Brief Summary of the trial: This trial is looking at how well a new drug Odronextamb combined with Chemotherapy works, and the safety of drug compared to Rituximab (already approved treatment)and Chemotherapy for follicular lymphoma.
Need to know: Must have not had any previous treatment for follicular lymphoma.
Where is this trial available? The Cancer and Hematology Centers and other various sites across the country. Please click on link above for more information.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of Trial: Olympia-3
What type of cancer is this for? Untreated patients with Diffuse Large B-Cell Lymphoma (DLBCL)
Phase of this trial? 3
Who is the trial for? Newly diagnosed patients with Diffuse large B-cell Lymphoma.
What biomarkers/mutations are necessary? CD20+
What is the National Clinical Trials info? NCT06091865
Brief summary of Trial: Patients who are eligible will receive standard of care chemotherapy (CHOP) plus investigational drug Odronextamab. Odronextamab is the investigation drug and will require frequent infusions/frequent check-in visits due to step-up dosing during the first 6 weeks. After the first 6 weeks treatment will be less frequent and may be given at any of our Cancer and Hematology centers. First 6 weeks will be done at our Grand Rapids site and will require patient to stay within 20 mins of hospital. Trial will supplement monies required for patients to be close to hospital.
Need to know: See above. Flexibility in staying at hotel near hospital in Grand Rapids is required and covered by study for 1-2 nights each week for the first 6 weeks. Newly being treated for this type of disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Melanoma Clinical Trials
Melanoma
NAME: IDE196-009
What kind of cancer is this for? Uveal melanoma
Phase: II
Who is this trial for? Men and women with primary uveal melanoma that requires either removal of the eye or radiation therapy.
What biomarkers are involved? None
What is National Clinical Trial #? NCT05907954
Brief summary of trial: This study is looking to see how people feel while they are taking the study drug, as well as how safe it is.
Need to know: The study drug is a pill, and you will have many eye exams during the trial.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
NAME: IDE196-002
What kind of cancer is this for? Metastatic Uveal melanoma
Phase: II/III
Who is this trial for? Men and women with uveal melanoma that has spread to other parts of their body.
What biomarkers are involved? None
What is National Clinical Trial #? NCT05987332
Brief summary of trial: This study is looking at how well the study drug (IDE196) plus crizotinib works, as well as how you feel when taking it.
Need to know: Your serotype must be HLA-A*02:01 negative.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of Trial: V940 (Merck)
What type of cancer is this for? Melanoma
Phase of this trial: Phase 3
Who is this trial for? Men and Women with high-risk stage II-IV melanoma.
What biomarkers are involved? none
What is National Clinical Trial #? NCT05933577
Brief summary of trial: A Phase 3 blinded clinical trial looking at a combination of Immunotherapy (pembrolizumab) plus V940 vaccine/placebo, in patients with surgically resected melanoma.
Need to know information: Individuals who have had surgical resection of Stage II-IV melanoma of the skin, who have not had any previous treatment beyond surgery.
Where is this trial available? The Cancer and Hematology Centers at Lemmon-Holton and other sites nationwide, click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Multiple Myeloma Clinical Trials
Multiple Myeloma
Name of this trial: EXCALIBER-Maintenance
What type of cancer is this for? Newly diagnosed Multiple Myeloma (NDMM)
Who is this trial for? 1) Patients who have received 3 to 6 cycles of an induction therapy. Post-stem cell transplant consolidation is permitted. 2) Patients within 12 months from initiation of induction who achieved at least a partial response after Autologous Stem Cell Transplantation, with or without consolidation.
What biomarkers are involved? None
What is the National Clinical Trial #? NCT05827016
Brief summary of this trial: The study is comparing Iberdomide maintenance vs. Lenalidomide maintenance therapy after Autologous Stem Cell Transplantation (ASCT) in patients with newly diagnosed multiple myeloma.
Need to know: Patients will be randomized 50:50 to either Iberdomide or Lenalidomide. Both medications are oral drugs, Iberdomide is taken 21 days out of a 28-day cycle, and Lenalidomide is taken 28 days out of a 28-day cycle. Treatment continues until progression of disease or until medications are not tolerated by patient.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Myelodysplastic Syndrome Clinical Trials
Multiple Myeloma
Name of this trial: EXCALIBER-Maintenance
What type of cancer is this for? Newly diagnosed Multiple Myeloma (NDMM)
Who is this trial for? 1) Patients who have received 3 to 6 cycles of an induction therapy. Post-stem cell transplant consolidation is permitted. 2) Patients within 12 months from initiation of induction who achieved at least a partial response after Autologous Stem Cell Transplantation, with or without consolidation.
What biomarkers are involved? None
What is the National Clinical Trial #? NCT05827016
Brief summary of this trial: The study is comparing Iberdomide maintenance vs. Lenalidomide maintenance therapy after Autologous Stem Cell Transplantation (ASCT) in patients with newly diagnosed multiple myeloma.
Need to know: Patients will be randomized 50:50 to either Iberdomide or Lenalidomide. Both medications are oral drugs, Iberdomide is taken 21 days out of a 28-day cycle, and Lenalidomide is taken 28 days out of a 28-day cycle. Treatment continues until progression of disease or until medications are not tolerated by patient.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Myelofibrosis Clinical Trials
Myelofibrosis
Name of Trial: Karyopharm XPORT-MF-034
What type of Cancer is this for? Myelofibrosis (Blood cancer)
Phase: 3
Who is this trial for? Patients with myelofibrosis or post-essential thrombocythemia (ET) or postpolycythemia-vera (PV) myelofibrosis.
What biomarkers involved? None
What is the National Clinical Trial #? NCT04562389
Brief Summary: Purpose of this study is to evaluate the drug Selinexor in combination with Ruxolitinib vs. Placebo plus Ruxolitinib. This is a double-blinded randomized clinical trial with 2:1 ratio.
Need to know: This trial is for patients who have not yet had any treatment for their blood cancer.
Where is this trial available? This trial is available at The Cancer and Hematology at Lemmon-Holton Cancer Pavilion, and at The Cancer and Hematology Centers in Muskegon. This trial is also available at other sites nationwide.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Pancreatic Cancer Clinical Trials
Pancreas
Prostate Cancer Clinical Trials
Prostate
Name of this trial: MK-5684-004
What type of cancer is this for? PROSTATE cancer
Phase of this trial? Phase III
Who is this trial for? Men with prostate cancer that has spread while taking a next generation hormonal agent.
What biomarkers are involved? None
What is the National Clinical Trial# NCT06136650
Brief summary of trial: This trial is comparing the study drug (MK-5684) to two other drugs, looking to prove that the study drug helps men live longer. It is randomized 1:1.
Need to know: Your prostate cancer must be castration resistant (cancer that continues to grow even when the testosterone levels are at or below the castrate level) and your disease has to have progressed when you were on or after you received a Next Generation Hormonal Agent such as enzalutamide, abiraterone acetate, apalutamide, and darolutamide.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of Trial: Evopar-Prostate
What type of cancer is this trial for? Patients with hormone resistant, metastatic castration-sensitive prostate cancer
What biomarkers are involved? None
National Clinical Trial # NCT06120491
Brief Summary of the trial: Patients with metastatic hormone-resistant and non-hormone resistant metastatic castration-sensitive prostate cancer, will receive physician’s choice of new hormonal agent in combination with either new drug AZD5305 vs. PLACEBO. This is a double-blinded study, which means neither patient nor provider will know whether patients are receiving AZD5305 drug or placebo.
Need to know information: These drugs are pills, not IV, and you may get placebo in combination with hormone agent.
Where is this trial available? The Cancer and Hematology Centers and other sites nationwide, please click on link above for other potential sites.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Registry Trials
Registry Trial
NAME: EXACT- Registry trial
What kind of cancer is this for? All cancer types
Phase: N/A
Who is this trial for? Men and women who either have a diagnosis of cancer, a clinical suspicion of cancer, a diagnosis of recurrent cancer or a clinical suspicion of recurrent cancer.
What biomarkers are involved? Multiple
What is National Clinical Trial #?
Brief summary of trial: This study is looking at tissue and blood samples from cancer patients, to study the biomarkers they find in the blood or tissue to help and come up with future therapies.
Need to know: There are no medications in this trial, you would need to give a blood or tissue sample for the sponsor to evaluate.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
NAME: Oracle- Registry trial
What kind of cancer is this for? All types
Phase: N/A
Who is this trial for? The primary study population will include participants with invasive bladder, ureteral, or renal pelvis carcinoma, non-small cell lung cancer, and breast cancer. Exploratory cohorts include participants with cutaneous melanoma, esophageal carcinoma, gastroesophageal junction carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, squamous cell carcinoma of the head and neck, epithelial ovarian/Fallopian tube carcinoma, endometrial cancer, renal cell carcinoma (RCC), and rectal adenocarcinoma.
What biomarkers are involved? None
What is National Clinical Trial #? NCT05059444
Brief summary of trial: This study wants to test an assay that they have developed, which could help detect recurrence in people with certain tumors.
Need to know: There are no medications on this trial, just blood draws and tissue samples are needed.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Urothelial Cancer Clinical Trials
Urothelial
Name of this trial: RC48 G001 (SEAGEN)
What type of cancer is this for? Locally advanced or metastatic Urothelial Carcinoma
Who is this trial for? Patients locally advanced, unresectable, or metastatic urothelial carcinoma, including urothelial originating from the renal pelvis, ureters, bladder, or urethra.
What biomarkers are involved? HER2 positive which will be centrally confirmed.
What is the National Clinical Trial #? NCT04879329
Brief summary of this trial: Trial is evaluating safety and efficacy of Disitamab Vedotin alone or in combination with Pembrolizumab. Patients who have had 1 or 2 previous lines of treatment will receive study drug every 2 weeks. Patients who have not been treated for locally advanced or metastatic disease will receive either study drug every 2 weeks with Pembrolizumab every 6 weeks, or study drug only every 2 weeks.
Need to know: Patients can have received 0, 1, or 2 lines of previous systemic therapy for locally or metastatic disease and progressed. Patients must have received an anti-PD-1 therapy.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com